Kaposi sarcoma - null regimens

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

The purpose of this page is to provide references to "null therapy" such as placebo and observation. While not clinically relevant, these references provide further insight into the historical development of the treatment landscape. See the main KS page for current regimens.

All lines of therapy



Study Dates of enrollment Evidence Comparator Comparative Efficacy
Noy et al. 2005 (AMC 013) 1998-2001 Phase 3 (C) IM862 Seems to have superior TTP

No active antineoplastic treatment.


  1. AMC 013: Noy A, Scadden DT, Lee J, Dezube BJ, Aboulafia D, Tulpule A, Walmsley S, Gill P; AIDS Malignancy Consortium. Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team. J Clin Oncol. 2005 Feb 10;23(5):990-8. Epub 2004 Dec 14. link to original article PubMed